Tackling Mantle Cell Lymphoma in Europe
暂无分享,去创建一个
E. Giné | M. Jerkeman | M. Dreyling | C. Visco | I. Aurer | J. Walewski | B. Fetica | M. G. da Silva | Marta Kozarić | D. Horgan
[1] A. Gajra,et al. Barriers to Chimeric Antigen Receptor T-Cell (CAR-T) Therapies in Clinical Practice , 2022, Pharmaceutical Medicine.
[2] E. Giné,et al. Outcome of COVID-19 in Patients With Mantle Cell Lymphoma—Report From the European MCL Registry , 2022, HemaSphere.
[3] K. Nan,et al. Global, regional and national burden of non-Hodgkin lymphoma from 1990 to 2017: estimates from global burden of disease study in 2017 , 2022, Annals of medicine.
[4] N. Huang,et al. Mantle cell lymphoma management trends and novel agents: where are we going? , 2022, Therapeutic advances in hematology.
[5] A. Taktak,et al. Mantle cell lymphoma treatment options for elderly/unfit patients: A systematic review , 2021, EJHaem.
[6] T. Pabst,et al. Outcome of patients with mantle cell lymphoma after autologous stem cell transplantation in the pre‐CAR T‐cell era , 2021, Hematological oncology.
[7] I. Aurer,et al. Improvement in the outcomes of mantle cell lymphoma in the last decade: a real-life non interventional study of the Croatian Cooperative Group for Hematologic Diseases , 2021, Croatian medical journal.
[8] A. Desai,et al. Progress in molecular feature of smoldering mantle cell lymphoma , 2021, Experimental Hematology & Oncology.
[9] B. Dholaria,et al. Balancing Quality, Cost, and Access During Delivery of Newer Cellular and Immunotherapy Treatments , 2021, Current Hematologic Malignancy Reports.
[10] M. Dreyling,et al. Mantle cell lymphoma – advances in molecular biology, prognostication and treatment approaches , 2021, British journal of haematology.
[11] G. Salles,et al. A French multicentric prospective prognostic cohort with epidemiological, clinical, biological and treatment information to improve knowledge on lymphoma patients: study protocol of the “REal world dAta in LYmphoma and survival in adults” (REALYSA) cohort , 2021, BMC Public Health.
[12] K. Maddocks,et al. Relapsed Mantle Cell Lymphoma: Current Management, Recent Progress, and Future Directions , 2021, Journal of clinical medicine.
[13] S. Ferrero,et al. Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma in the Era of New Drugs and CAR-T Cell Therapy , 2021, Cancers.
[14] K. Grønbæk,et al. Detailed Long-Term Follow-Up of Patients Who Relapsed After the Nordic Mantle Cell Lymphoma Trials: MCL2 and MCL3 , 2020, HemaSphere.
[15] M. Ghielmini,et al. Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.
[16] P. Pophali,et al. Understanding Health-Related Quality of Life in Patients with Mantle Cell Lymphoma. , 2020, Hematology/oncology clinics of North America.
[17] M. Dreyling,et al. EHA Endorsement of ESMO Clinical Practice Guidelines for Newly Diagnosed and Relapsed Mantle Cell Lymphoma , 2020, HemaSphere.
[18] S. Hohaus,et al. Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study , 2020, Leukemia.
[19] E. Campo,et al. Molecular Pathogenesis of Mantle Cell Lymphoma. , 2020, Hematology/oncology clinics of North America.
[20] A. Kent,et al. Time for Change? The Why, What and How of Promoting Innovation to Tackle Rare Diseases – Is It Time to Update the EU’s Orphan Regulation? And if so, What Should be Changed? , 2020, Biomedicine Hub.
[21] C. Pott,et al. Minimal residual disease (MRD) in mantle cell lymphoma , 2020 .
[22] N. Epperla,et al. Emerging therapies in mantle cell lymphoma , 2020, Journal of Hematology & Oncology.
[23] S. Rule,et al. The 5‐year follow‐up of a real‐world observational study of patients in the United Kingdom and Ireland receiving ibrutinib for relapsed/refractory mantle cell lymphoma , 2020, British journal of haematology.
[24] J. Eriksson,et al. Stated preferences for relapsed or refractory mantle cell lymphoma treatments in Sweden and Germany. , 2020, Future oncology.
[25] J. Richter,et al. Integrating Best Practices to Improve Outcomes in Relapsed/Refractory Multiple Myeloma , 2020, Journal of the advanced practitioner in oncology.
[26] E. Macintyre,et al. Droplet Digital PCR Quantification of Mantle Cell Lymphoma Follow-up Samples From Four Prospective Trials of the European MCL Network , 2020, HemaSphere.
[27] J. Ruan. Molecular profiling and management of mantle cell lymphoma. , 2019, Hematology. American Society of Hematology. Education Program.
[28] P. Jain,et al. Mantle cell lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication, and management , 2019, American journal of hematology.
[29] E. Epner,et al. Mantle cell lymphoma and its management: where are we now? , 2019, Experimental Hematology & Oncology.
[30] B. Seal,et al. Adverse events, resource use, and economic burden associated with mantle cell lymphoma: a real-world assessment of privately insured patients in the United States , 2018, Leukemia & lymphoma.
[31] D. Šálek,et al. Maintenance rituximab in newly diagnosed mantle cell lymphoma patients: a real world analysis from the Czech lymphoma study group registry† , 2018, Leukemia & lymphoma.
[32] A. Rosenwald,et al. Validation of the MCL35 gene expression proliferation assay in randomized trials of the European Mantle Cell Lymphoma Network , 2018, British journal of haematology.
[33] E. González-Barca,et al. Spanish Lymphoma Group (GELTAMO) guidelines for the diagnosis, staging, treatment, and follow-up of diffuse large B-cell lymphoma , 2018, Oncotarget.
[34] P. Zinzani,et al. Treatment for patients with relapsed/refractory mantle cell lymphoma: European-based recommendations , 2018, Leukemia & lymphoma.
[35] L. Gordon,et al. Current overview and treatment of mantle cell lymphoma , 2018, F1000Research.
[36] Michael L. Wang,et al. NF-κB signaling and its relevance to the treatment of mantle cell lymphoma , 2018, Journal of Hematology & Oncology.
[37] Michael L. Wang,et al. Frontline Treatment for Older Patients with Mantle Cell Lymphoma. , 2018, The oncologist.
[38] L. Costa,et al. Incidence and survival trends in mantle cell lymphoma , 2018, British journal of haematology.
[39] A. Rosenwald,et al. Expression of TP53 is associated with the outcome of MCL independent of MIPI and Ki-67 in trials of the European MCL Network. , 2018, Blood.
[40] M. André,et al. Updated BHS guidelines for the treatment of chronic lymphocytic leukaemia , mantle cell lymphoma and Waldenström macroglobulinemia anno 2018 , 2018 .
[41] S. Montoto,et al. Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT Chronic Malignancies and Lymphoma Working Parties , 2018, Bone Marrow Transplantation.
[42] N. Monga,et al. Review Of Real-World Evidence To Assess The Burden Of Illness Of Mantle Cell Lymphoma , 2017 .
[43] B. Shah,et al. Mantle Cell Lymphoma: Contemporary Diagnostic and Treatment Perspectives in the Age of Personalized Medicine. , 2017, Hematology/oncology and stem cell therapy.
[44] S. Ferrero,et al. Minimal residual disease in mantle cell lymphoma: are we ready for a personalized treatment approach? , 2017, Haematologica.
[45] M. Ladetto,et al. Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[46] S. Rule. Frontline therapy and role of high-dose consolidation in mantle cell lymphoma. , 2016, Hematology. American Society of Hematology. Education Program.
[47] M. Kolek,et al. New Approach to Budget Impact Analysis - Ibrutinib In Treatment of Relapsed/Refractory Cll Patients in The Czech Republic , 2016 .
[48] K. Young,et al. Diagnostic and predictive biomarkers for lymphoma diagnosis and treatment in the era of precision medicine , 2016, Modern Pathology.
[49] A. Rosenwald,et al. Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma Network. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[50] A. Inamdar,et al. Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agents , 2016, Oncotarget.
[51] S. Ferrero,et al. The role of targeted treatment in mantle cell lymphoma: is transplant dead or alive? , 2016, Haematologica.
[52] S. Ferrero,et al. Personalized medicine in lymphoma: is it worthwhile? The mantle cell lymphoma experience , 2015, Haematologica.
[53] C. Leux,et al. Mantle cell lymphoma epidemiology: a population-based study in France , 2014, Annals of Hematology.
[54] J. Vose. Mantle cell lymphoma: 2013 Update on diagnosis, risk‐stratification, and clinical management , 2013, American journal of hematology.
[55] B. Shah,et al. Mantle cell lymphoma: a clinically heterogeneous disease in need of tailored approaches. , 2012, Cancer control : journal of the Moffitt Cancer Center.
[56] B. Hancock,et al. The Mantle Cell Lymphoma International Prognostic Index: Does it work in routine practice? , 2010, Oncology letters.